Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Olivier Bouché

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-8284-3743; OpenAlex author ID A5077000250, A5106036588. Sources: OpenAlex.

Their work

Papers
36 (first author 2, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
118
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: 2 papers · 2014: none · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: none · 2020: 3 papers · 2021: 2 papers · 2022: 4 papers · 2023: 4 papers · 2024: 6 papers · 2025: 4 papers · 2026: 5 papers

Papers 36

  1. Prognostic and predictive values of transcriptomic signatures in metastatic pancreatic cancer: A biomarker analysis of three French multicenter prospective ran… Co-author DOI 10.1016/j.canlet.2026.218745↗
  2. Optimizing first-line NALIRIFOX and exploring the role of the microbiota in second-line pancreatic cancer treatment: the PRODIGE 105-GERCOR 116 PANORAMIX trial. Co-author DOI 10.1016/j.dld.2026.10.006↗
  3. Characterisation of early-onset pancreatic adenocarcinoma molecular profile compared to average-onset pancreatic adenocarcinoma (CARAPAC): A systematic review … Co-author DOI 10.1016/j.pan.2026.03.002↗
  4. Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer. Co-author DOI 10.1038/s41586-026-10436-4↗
  5. Reply to: "FOLFIRINOX for Locally Advanced Pancreatic Cancer: The Need for Individualized Strategies," "Conversion Chemotherapy for Locally Advanced Pancreatic… Last author DOI 10.1200/jco-25-02162↗
  6. Molecular analysis in pancreatic adenocarcinoma: a real-world study from high-volume French centres (CAPANCOBIO study). Co-author DOI 10.1016/j.esmogo.2025.100142↗
  7. Impact of low muscle mass and myosteatosis on treatment toxicity and survival outcomes in non-resectable pancreatic cancer patients treated with chemoradiother… Last author DOI 10.1038/s41430-025-01566-5↗
  8. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PROD… Co-author DOI 10.1200/jco-24-01378↗
  9. TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreat… Co-author DOI 10.1200/jco-25-00872↗
  10. Association between pancreatic adenocarcinoma risk and concentration of organochlorine pesticides in adipose tissue and urine: A targeted-screening analysis ca… Last author DOI 10.1002/ueg2.12602↗
  11. Pesticides and risk of pancreatic adenocarcinoma in France: a nationwide spatiotemporal ecological study between 2011 and 2021. Co-author DOI 10.1007/s10654-024-01176-8↗
  12. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.annonc.2024.06.010↗
  13. Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective… Co-author DOI 10.1016/j.ejca.2024.115051↗
  14. Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyae079↗
  15. Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Pha… Co-author DOI 10.1200/jco.23.00795↗
  16. Association of palliative care management and survival after chemotherapy discontinuation in patients with advanced pancreatic adenocarcinoma: A retrospective … Last author DOI 10.1016/j.pan.2023.03.005↗
  17. Genetic counselling referral practices for patients with pancreatic adenocarcinoma: A French retrospective multicentre observational cohort study (CAPANCOGEN). Last author DOI 10.1016/j.pan.2023.06.010↗
  18. Beta-blocker exposure and survival outcomes in patients with advanced pancreatic ductal adenocarcinoma: a retrospective cohort study (BETAPANC). Co-author DOI 10.3389/fphar.2023.1137791↗
  19. Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial. First author DOI 10.6004/jnccn.2023.7065↗
  20. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2022.3829↗
  21. Pesticides and pancreatic adenocarcinoma: A transversal epidemiological, environmental and mechanistic narrative review. Last author DOI 10.1016/j.dld.2022.08.023↗
  22. Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective obs… Last author DOI 10.1016/j.ejca.2022.01.040↗
  23. Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival? Co-author DOI 10.3389/fonc.2022.980659↗
  24. Time from first seen in specialist care to surgery does not influence survival outcome in patients with upfront resected pancreatic adenocarcinoma. First author DOI 10.1186/s12893-021-01409-7↗
  25. Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. Co-author DOI 10.1200/jco.20.03329↗
  26. Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic adenocarcinoma. Last author DOI 10.1016/j.dld.2020.03.014↗
  27. Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized … Co-author DOI 10.1016/j.ejca.2019.10.020↗
  28. Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label,… Co-author DOI 10.1016/j.ejca.2020.02.004↗
  29. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Co-author DOI 10.1016/j.dld.2018.08.008↗
  30. Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis. Co-author DOI 10.1016/j.pan.2016.12.009↗
  31. Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1093/jnci/djx037↗
  32. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Wi… Co-author DOI 10.1001/jama.2016.4324↗
  33. Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. Co-author DOI 10.1093/annonc/mdt176↗
  34. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomize… Co-author DOI 10.1200/jco.2012.44.4869↗
  35. [Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results … Co-author DOI 10.1016/j.canrad.2010.10.001↗
  36. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. Co-author DOI 10.1056/nejmoa1011923↗

Closest collaborators

The 25 strongest of 118 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mathias Brügel · 13 shared papers, 2020–2026 · strength 2.43
  2. Jean‐Baptiste Bachet · 12 shared papers, 2011–2026 · strength 1.54
  3. Nicolas Williet · 8 shared papers, 2018–2026 · strength 1.28
  4. David Tougeron · 7 shared papers, 2020–2025 · strength 1.00
  5. Gaël S. Roth · 5 shared papers, 2022–2026 · strength 0.95
  6. Marine Perrier · 5 shared papers, 2023–2025 · strength 0.94
  7. Anthony Turpin · 6 shared papers, 2021–2026 · strength 0.88
  8. Cindy Neuzillet · 7 shared papers, 2017–2026 · strength 0.87
  9. Pascal R. Hammel · 9 shared papers, 2011–2025 · strength 0.80
  10. Jerome F. Cros · 5 shared papers, 2020–2026 · strength 0.76
  11. Camille Evrard · 4 shared papers, 2022–2026 · strength 0.71
  12. Louis de Mestier · 5 shared papers, 2017–2026 · strength 0.61
  13. Michaël Génin · 2 shared papers, 2024–2026 · strength 0.59
  14. Florian Slimano · 3 shared papers, 2023–2025 · strength 0.59
  15. Tullio Piardi · 4 shared papers, 2021–2024 · strength 0.56
  16. Isabelle Trouilloud · 3 shared papers, 2024–2026 · strength 0.56
  17. Christophe Tournigand · 5 shared papers, 2017–2025 · strength 0.53
  18. Michel Pierre Ducreux · 2 shared papers, 2011–2026 · strength 0.52
  19. David Malka · 3 shared papers, 2021–2026 · strength 0.50
  20. Julien Taı̈eb · 3 shared papers, 2018–2026 · strength 0.46
  21. Thierry Conroy · 5 shared papers, 2011–2024 · strength 0.41
  22. Laëtitia Dahan · 3 shared papers, 2018–2026 · strength 0.41
  23. Marie Müller · 2 shared papers, 2024–2025 · strength 0.40
  24. Brice Chanez · 2 shared papers, 2024–2026 · strength 0.40
  25. Fabienne Portales · 4 shared papers, 2018–2025 · strength 0.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.